Tg Therapeutics, Inc. financial data

Symbol
TGTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2 Gansevoort Street, 9 Th Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
MANHATTAN PHARMACEUTICALS INC (to 4/27/2012), ATLANTIC TECHNOLOGY VENTURES INC (to 3/10/2003), ATLANTIC PHARMACEUTICALS INC (to 2/4/2000)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 434 % +31.3%
Quick Ratio 72.7 %
Debt-to-equity 116 % -56.1%
Return On Equity -310 %
Return On Assets 26.7 %
Operating Margin -6.92K % -34.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 155M shares +2.55%
Common Stock, Shares, Outstanding 155M shares +2.59%
Entity Public Float 3.4B USD +502%
Common Stock, Value, Issued 155K USD +2.65%
Weighted Average Number of Shares Outstanding, Basic 145M shares +2.28%
Weighted Average Number of Shares Outstanding, Diluted 159M shares +12.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.79M USD -58.4%
Revenue from Contract with Customer, Excluding Assessed Tax 347M USD +1342%
Research and Development Expense 82.5M USD -12.7%
Costs and Expenses 245M USD +6.42%
Operating Income (Loss) 102M USD
Nonoperating Income (Expense) -6.07M USD +12.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6.55M USD
Income Tax Expense (Benefit) -328K USD
Net Income (Loss) Attributable to Parent 95.7M USD
Earnings Per Share, Basic 0.69 USD/shares
Earnings Per Share, Diluted 0.04 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 82.9M USD -14.5%
Cash, Cash Equivalents, and Short-term Investments 217M USD
Accounts Receivable, after Allowance for Credit Loss, Current 83.6M USD
Inventory, Net 81.2M USD +169%
Other Assets, Current 7.05M USD -36.4%
Assets, Current 389M USD +86.6%
Property, Plant and Equipment, Net 66K USD -72.2%
Operating Lease, Right-of-Use Asset 7.66M USD -9.58%
Goodwill 799K USD 0%
Other Assets, Noncurrent 2.16M USD
Assets 401M USD +81.7%
Liabilities, Current 109M USD +49.5%
Operating Lease, Liability, Noncurrent 8.7M USD -11.3%
Liabilities 224M USD +24%
Retained Earnings (Accumulated Deficit) -1.56B USD +3.56%
Stockholders' Equity Attributable to Parent 178M USD +339%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 40.5M USD -68.7%
Liabilities and Equity 401M USD +81.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.21M USD +86.3%
Net Cash Provided by (Used in) Financing Activities 10M USD -60.4%
Net Cash Provided by (Used in) Investing Activities -9.26M USD -50%
Common Stock, Shares Authorized 190M shares +8.57%
Common Stock, Shares, Issued 155M shares +2.59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.5M USD +57.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 84.2M USD -14.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.45M USD +40%
Deferred Tax Assets, Valuation Allowance 418M USD +4.48%
Deferred Tax Assets, Gross 418M USD +4.48%
Operating Lease, Liability 10M USD -11.6%
Depreciation 68K USD -10.5%
Payments to Acquire Property, Plant, and Equipment 7K USD -89.6%
Lessee, Operating Lease, Liability, to be Paid 13.8M USD -14.7%
Operating Lease, Liability, Current 1.31M USD -13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.08M USD -0.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.1M USD -12.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.83M USD -21.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.91M USD -8.03%
Deferred Tax Assets, Operating Loss Carryforwards 317M USD +4.36%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.83M USD -4.5%
Operating Lease, Payments 600K USD
Additional Paid in Capital 1.73B USD +4.81%
Amortization of Intangible Assets 53K USD 0%
Depreciation, Depletion and Amortization 29K USD -57.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 37.4M USD -24%
Interest Expense 12.1M USD +16.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%